MX2023007029A - Masitinib para el tratamiento de la enfermedad de alzheimer. - Google Patents
Masitinib para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2023007029A MX2023007029A MX2023007029A MX2023007029A MX2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- masitinib
- treatment
- solvate
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 5
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 4
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004655 masitinib Drugs 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306589 | 2020-12-16 | ||
| PCT/EP2021/086308 WO2022129410A1 (en) | 2020-12-16 | 2021-12-16 | Masitinib for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007029A true MX2023007029A (es) | 2023-07-18 |
Family
ID=74141317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007029A MX2023007029A (es) | 2020-12-16 | 2021-12-16 | Masitinib para el tratamiento de la enfermedad de alzheimer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058328A1 (enExample) |
| EP (1) | EP4262801A1 (enExample) |
| JP (1) | JP2023554354A (enExample) |
| KR (1) | KR20230125804A (enExample) |
| CN (1) | CN116963736A (enExample) |
| AU (1) | AU2021399925A1 (enExample) |
| CA (1) | CA3201259A1 (enExample) |
| IL (1) | IL303521A (enExample) |
| MX (1) | MX2023007029A (enExample) |
| WO (1) | WO2022129410A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| AR080380A1 (es) * | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
-
2021
- 2021-12-16 US US18/256,721 patent/US20240058328A1/en active Pending
- 2021-12-16 KR KR1020237023563A patent/KR20230125804A/ko active Pending
- 2021-12-16 CA CA3201259A patent/CA3201259A1/en active Pending
- 2021-12-16 JP JP2023536086A patent/JP2023554354A/ja active Pending
- 2021-12-16 CN CN202180093808.7A patent/CN116963736A/zh active Pending
- 2021-12-16 AU AU2021399925A patent/AU2021399925A1/en active Pending
- 2021-12-16 MX MX2023007029A patent/MX2023007029A/es unknown
- 2021-12-16 EP EP21839188.6A patent/EP4262801A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086308 patent/WO2022129410A1/en not_active Ceased
- 2021-12-16 IL IL303521A patent/IL303521A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116963736A (zh) | 2023-10-27 |
| WO2022129410A1 (en) | 2022-06-23 |
| EP4262801A1 (en) | 2023-10-25 |
| KR20230125804A (ko) | 2023-08-29 |
| AU2021399925A1 (en) | 2023-06-29 |
| JP2023554354A (ja) | 2023-12-27 |
| US20240058328A1 (en) | 2024-02-22 |
| IL303521A (en) | 2023-08-01 |
| CA3201259A1 (en) | 2022-06-23 |
| AU2021399925A9 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018112446A3 (en) | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease | |
| WO2006071778A3 (en) | Treatment of parkinson's disease and related disorders using postpartum derived cells | |
| WO2004010932A3 (en) | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions | |
| MX2007001679A (es) | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| MX2022009285A (es) | Inhibidores macrocíclicos de la quinasa rip2. | |
| TR201809537T4 (tr) | Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. | |
| TW201412325A (zh) | 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療 | |
| FI2765988T3 (fi) | Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| PH12023550900A1 (en) | Oral combined formulation including gemigliptin and dapagliflozin and preparation method therefor | |
| WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
| Kadir et al. | A case of acute periorbital necrotizing fasciitis | |
| JP2023554354A5 (enExample) | ||
| ATE447963T1 (de) | Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung | |
| CN107184744A (zh) | 番茄红素和葡萄籽提取物的组合物在制药中的用途 | |
| ZA202200331B (en) | Naltrexone formulation | |
| MX2023005663A (es) | Tratamientos respiratorios. |